Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided efficacy/label indication claims for SCEMBLIX (Scemblix) match the supplied FDA label Indications and Usage text. No contraindications, boxed warnings, dosing, or safety population claims were provided, so those label sections cannot be assessed for accuracy.
Category Scores
Accurate Statements
SCEMBLIX is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
1 INDICATIONS AND USAGE (newly diagnosed Ph+ CML in CP; accelerated approval language present in label excerpt)
SCEMBLIX is indicated for the treatment of adult patients with previously treated Ph+ CML in CP.
1 INDICATIONS AND USAGE (previously treated Ph+ CML in CP)
SCEMBLIX is indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.
1 INDICATIONS AND USAGE (Ph+ CML in CP with the T315I mutation)
Unsupported Statements
Contradictions
Important Omissions
The initial user-provided list included non-indication claims (e.g., manufacturer/developer/marketing statements, that it is used as a BCR::ABL1 inhibitor). These were not evaluated against label excerpts because the audit input only contained Indications and Usage and a mechanism-of-action excerpt for the last point, not the manufacturer/developer/market geography statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The audited content contains only indication-alignment determinations; no dosing, contraindications, boxed warnings, or population-specific safety claims were asserted or evaluated in a potentially unsafe way.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The audit did not assess non-indication statements from the user prompt (e.g., marketing/developer/manufacturer assertions) because they were not supported by the provided label excerpts.
Suggested Improvement
Limit evaluation to label-supported sections provided, and explicitly state when company/manufacturer/market-specific claims cannot be verified from the supplied prescribing information excerpts.